MULPLETA (lusutrombopag) 

SELF ADMINISTRATION - ORAL

Indications for Prior Authorization:
  • Treatment of thromobocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure
Patients must meet the following criteria for the indications above:
  • Patient is at least 18 years of age and has a documented diagnosis of chronic liver disease, AND
  • Patient has a current platelet count < 50 x 109, AND
  • The patient is scheduled to undergo an invasive procedure with intermediate-to-high bleeding risk (e.g, spinal surgery, cardiac surgery, large polypectomy, liver biopsy) within 8-14 days after starting Mulpleta therapy
  • Not approvable for a patient who is undergoing a low-risk procedure (e.g. spinal surgery, cardiac surgery, large polypectome, liver biopsy) within 8-14 days after starting Mulpleta therapy
  • Not approvable for a patient who is undergoing a low-risk procedure (e.g. paracentesis, routine endoscopay, or central line placement)
  • Not approvable to be administered to patients with chronic liver disease in an attempt to normalize platelet counts
Dosing:
  • Begin Mulpleta 8-14 days prior to a scheduled procedure
  • Patients should undergo their procedure 2-8 days after the last dose
  • The recommended dosing is 3 mg orally once daily for 7 days
Approval:
  • One 7 day course

Last review date: June 10, 2019

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone